Copper Nanozyme Boosts Tumor Therapy Precision

Research into cancer treatment continues to be a paramount concern for the medical community, particularly due to the ongoing challenges surrounding precision and side effects in malignant tumor therapies. A recent study has introduced a new avenue for treatment with the development of a copper-based single-atom nanozyme that exhibits significant tumor suppression capabilities with heightened precision.

The Innovation of Copper Single-Atom Nanozymes

The practical application of copper-based nanozymes in tumor therapy has faced obstacles such as weak substrate adsorption and the complexities involved in synthesizing low-coordination unsaturated structures. However, a collaborative research team, spearheaded by Professor Wang Hui from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences (CAS), has successfully engineered a coordination-unsaturated copper single-atom nanozyme. This advancement is documented in the journal Advanced Functional Materials.

Synthesis and Mechanism of Action

The study introduced an innovative ligand chelation conformation strategy, wherein the researchers utilized ethylenediaminetetraacetic acid (EDTA) and copper chloride as precursors. They fashioned a carbon dot-supported, coordinatively unsaturated Cu-N2 single-atom nanozyme (denoted as Cu-N2\-CDs) through a one-step hydrothermal method. A coordinatively saturated counterpart, the Cu-N4 nanozyme (Cu-N4\-CDs), was also synthesized for comparative analysis. The Cu-N2\-CDs display dual enzyme-like activities that mimic both peroxidase and glutathione peroxidase within the tumor microenvironment.

To better understand the therapeutic potential of these nanozymes, the team utilized an electron paramagnetic resonance spectrometer at the Steady High Magnetic Field Facility. This allowed for the monitoring of in situ hydroxyl radical (·OH) generation, thus elucidating the structure-activity relationship between the metal coordination environment and key factors pertinent to substrate adsorption and electron transfer efficiency.

Key Findings

Experimental Efficacy

The research team conducted both in vitro and in vivo experiments that showcased the superior anti-tumor efficacy of Cu-N2\-CDs. Results indicated a marked reduction in cancer cell viability as well as enhanced tumor suppression compared to the Cu-N4\-CDs in various cell studies. Additionally, these nanozymes enable precise tumor imaging-guided therapy while also demonstrating commendable biosafety profiles.

“The creation of Cu-N2\-CDs marks a significant step in advancing cancer treatment methodologies, highlighting the importance of tailored approaches to enhance therapeutic efficacy while minimizing adverse effects,” said Lin Yefeng, a member of the research team.

Future Implications

The findings from this study not only propel the knowledge of copper nanozymes but also pave the way for further investigations into their practical applications in clinical oncology. The development emphasizes the necessity to explore other reactive nanozymes that can be engineered to target specific tumor characteristics and enhance precision therapy.

Conclusion

The promising results obtained from the Cu-N2\-CDs and their unique catalytic mechanisms offer a glimmer of hope in the realm of tumor therapy. Continued research and development will be crucial in translating these findings from laboratory settings to clinical applications.

References

Yefeng Lin et al, Enhanced Catalytic Therapy by Modulating Substrate Adsorption and Local Electron Density through Coordinatively Unsaturated Cu‐N2 Single‐Atom Sites on Carbon Dots, Advanced Functional Materials (2026).

For further details, you may refer to the original article at: Science X News.